BlissCo Appoints New CFO to Take Company Through Next Phase of Growth

Not for distribution in the U.S. or to U.S. Newswires

VANCOUVER, British Columbia, Oct. 22, 2018 (GLOBE NEWSWIRE) --  BlissCo Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B), (“BlissCo”) or the (“Company”) is pleased to announce the appointment of Jennifer Archibald as the Company’s Chief Financial Officer.

Ms. Archibald is a seasoned executive with over two decades of experience in complex, multi-national public and private companies across a broad range of industries including most recently, the pharmaceutical industry. 

During her tenure at Correvio Pharma Corp. (“Correvio”), a Nasdaq and TSX-traded pharmaceutical company, where she served as CFO and Chief Business Operations Officer, Ms. Archibald completed multiple business development and financing transactions that raised over $200 million. Prior to joining Correvio, Ms. Archibald managed the accounting operations at the corporate office of The Jim Pattison Group, the second largest private company in Canada.

“We are thrilled that Jennifer is joining our team as CFO. Her vast experience in capital markets, corporate strategy, mergers and acquisitions, and financial management will help to accelerate BlissCo’s growth,” said Damian Kettlewell, CEO and Founder of BlissCo Cannabis Corp. “Her background in the pharmaceutical industry and understanding of the unique challenges of high-growth, startup stage, global organizations will be a tremendous asset to BlissCo.”

“I am elated to join the growing BlissCo team at such an exciting time,” said Ms. Archibald.  “With opportunities abound, the Company is poised for significant growth in a rapidly developing industry. I look forward to working with the team to create meaningful shareholder value during this dynamic period of growth in the sector.”

Ms. Archibald was the recipient of Business in Vancouver’s BC CFO Award in 2016 and Top 40 Under 40 award in 2014 for her role in transforming Correvio into a revenue generating international specialty pharmaceutical company. She is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce degree from the University of British Columbia in Canada.

Ms. Archibald replaces Sean Ty, who served as interim CFO, and who will continue in his role as the Company’s Controller. The Company would like to thank Mr. Ty for his dedication to the Company and acting as its interim CFO.

About BlissCo Cannabis Corp.
BlissCo Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a wellness-focused, ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships. 

BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets.

BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo's future patients and customers.

Learn more: BlissCo.com

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

For further information please contact:

Ariel Jack Lewinski, Business Development & Investor Relations

# 1-604-377-7533
ariel.lewinski@blissco.com

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.